|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC102B |
Gene summary for CCDC102B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC102B | Gene ID | 79839 |
| Gene name | coiled-coil domain containing 102B | |
| Gene Alias | ACY1L | |
| Cytomap | 18q22.1-q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q68D86 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79839 | CCDC102B | ATC11 | Human | Thyroid | ATC | 1.02e-03 | 3.45e-01 | 0.3386 |
| 79839 | CCDC102B | ATC12 | Human | Thyroid | ATC | 1.09e-24 | 7.71e-01 | 0.34 |
| 79839 | CCDC102B | ATC13 | Human | Thyroid | ATC | 3.42e-58 | 1.18e+00 | 0.34 |
| 79839 | CCDC102B | ATC4 | Human | Thyroid | ATC | 8.80e-33 | 9.55e-01 | 0.34 |
| 79839 | CCDC102B | ATC5 | Human | Thyroid | ATC | 4.74e-67 | 1.24e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC102B | SNV | Missense_Mutation | rs199750681 | c.23G>A | p.Arg8Gln | p.R8Q | Q68D86 | protein_coding | tolerated(0.1) | benign(0.11) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CCDC102B | SNV | Missense_Mutation | c.610C>A | p.Gln204Lys | p.Q204K | Q68D86 | protein_coding | tolerated(0.78) | benign(0.003) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| CCDC102B | SNV | Missense_Mutation | c.751G>A | p.Glu251Lys | p.E251K | Q68D86 | protein_coding | tolerated(0.08) | benign(0.067) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC102B | SNV | Missense_Mutation | rs368864406 | c.832N>T | p.Arg278Cys | p.R278C | Q68D86 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC102B | SNV | Missense_Mutation | c.553N>G | p.Arg185Gly | p.R185G | Q68D86 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC102B | SNV | Missense_Mutation | rs368864406 | c.832N>T | p.Arg278Cys | p.R278C | Q68D86 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC102B | SNV | Missense_Mutation | rs746788896 | c.485G>T | p.Gly162Val | p.G162V | Q68D86 | protein_coding | tolerated(0.18) | benign(0.077) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| CCDC102B | insertion | In_Frame_Ins | novel | c.272_273insGAATTATGTATCTTTAAAACTTAACTCTGCTTCTCT | p.Thr91_Met92insAsnTyrValSerLeuLysLeuAsnSerAlaSerLeu | p.T91_M92insNYVSLKLNSASL | Q68D86 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CCDC102B | deletion | Frame_Shift_Del | novel | c.1079delN | p.Ser361ArgfsTer23 | p.S361Rfs*23 | Q68D86 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CCDC102B | SNV | Missense_Mutation | novel | c.1033N>G | p.Ile345Val | p.I345V | Q68D86 | protein_coding | tolerated(0.14) | benign(0.028) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |